EVAX – evaxion biotech a/s - american depositary share (US:NASDAQ)
Stock Stats
News
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Evaxion announces business update and third quarter 2024 financial results
Evaxion to announce business update and third quarter 2024 financial results on October 31
Form F-1 Evaxion Biotech A/S
Form SC 13G Evaxion Biotech A/S Filed by: ARMISTICE CAPITAL, LLC
Form 6-K Evaxion Biotech A/S For: Nov 13
Form 6-K Evaxion Biotech A/S For: Nov 13
Form 6-K Evaxion Biotech A/S For: Nov 13
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.